Home › Overweight › California › Long Beach
Overweight clinical trials in Long Beach, CA
5 studies for Overweight are looking for participants at sites in and around Long Beach (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes
RecruitingPhase 3
- Ark Clinical Research, Long Beach
A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity
RecruitingPhase 3
- Healthy Brain Clinic, Long Beach
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
RecruitingPhase 3
- Ark Clinical Research, Long Beach
A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight
RecruitingPhase 3
- Ark Clinical Research, Long Beach
Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)
RecruitingPhase 3
- Long Beach Clinical Trials Services Inc, Long Beach
- Ark Clinical Research- Long Beach, Long Beach
Overweight trials in other cities
- San Antonio, TX34 studies
- Houston, TX33 studies
- Chicago, IL29 studies
- Orlando, FL27 studies
- Dallas, TX23 studies
- Miami, FL23 studies
- Washington, DC20 studies
- Atlanta, GA20 studies
- Austin, TX19 studies
- Las Vegas, NV19 studies
- Jacksonville, FL19 studies
- New York City, NY19 studies
Other studies in Long Beach
- Non-Small Cell Lung Cancer11 studies
- Alzheimer's Disease10 studies
- Type 2 Diabetes10 studies
- Breast Cancer8 studies
- Lung Cancer8 studies
- Cancer (all types)6 studies
- Prostate Cancer6 studies
- Dementia5 studies
- Obesity5 studies
- Cardiovascular Disease5 studies
- Migraine5 studies
- Mild Cognitive Impairment4 studies
From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.